Trial intelligence / Profile preview

SOX perioperative or adjuvant chemotherapy versus XELOX adjuvant chemotherapy after D2 gastrectomy for locally advanced gastric adenocarcinoma

ChiCTR-IPR-15006283Phase 4Recruiting

Sponsor
Peking University Cancer Hospital & Institute
Start
Jun 2012
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised, open-label trial of oxaliplatin, tegafur and capecitabine in gastric adenocarcinoma (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: 3-year disease-free survival rate. Started Jun 2012; status: recruiting.

02

Drugs

oxaliplatintegafurcapecitabine
03

Conditions

gastric adenocarcinoma

Beyond the preview

Go deeper on ChiCTR-IPR-15006283.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IPR-15006283.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call